Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNexsen Limited

Nexsen Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.15 AUD -0.01 ( 6.25%)
Last update at 2026-11-12T04:48:00Z
VOLUME
54955
Market Cap
32.32M

Momentum Score

…

Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella. The company was incorporated in 2021 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.15
Low
0.15
High
52 Week Price Range
0.10
Low
0.34
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nexsen Limited is an Australia-listed company; public disclosures are limited and its core business and operations are not clearly described in readily available sources. Because of this opacity, prospective long-term growth drivers are uncertain, although improved disclosure combined with successful strategic execution and expansion of any identified activities could support value over time and may benefit investors monitoring progress.

Key investment risks include low liquidity and small-cap trading volatility, execution and financing risk if capital is required to scale operations, and regulatory or sector exposure that will depend on the company's actual activities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
-
Revenue TTM
0.93M
Revenue Per Share
0.01
Gross Profit TTM
-3.16M
Debt / Equity
-
ROE
-236.38%
Net Debt
-
ROCE
-120.95%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30
Type yearly
Date 2026-06-30
Income before tax -6.55M
Net income -6.55M
Selling general administrative 2.87M
Reconciled depreciation 0.00M
Operating income -6.86M
Interest expense 0.78M
Tax provision 0.00M
Net interest income -0.69M
Total other income expense net 1.00M
Net income from continuing ops -6.55M
Breakdown 2026-06-30
Type yearly
Date 2026-06-30
Total assets 6.70M
Intangible assets 1.70M
Other current assets 0.03M
Total liab 1.04M
Total stockholder equity 5.66M
Capital stock 15.94M
Retained earnings -11.78M
Cash 4.49M
Total current liabilities 1.03M
Total current assets 4.99M
Long term investments 0.00M
Accounts payable 0.83M
Non current assets total 1.71M
Capital lease obligations 0.01M
Breakdown 2026-06-30
Type yearly
Date 2026-06-30
Total cash from financing activities 7.41M
Net income -6.55M
Change in cash 4.07M
Begin period cash flow 0.42M
End period cash flow 4.49M
Issuance of capital stock 7.41M
Capital expenditures 0.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
NXN
Nexsen Limited		 -0.01
6.25%		 0.15 - - 40.83 5.71
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36

Profile*

Nexsen Limited

Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella. The company was incorporated in 2021 and is based in Sydney, Australia.

4 Bridge Street, Sydney, NSW, Australia, 2000

61 2 9174 5388

https://www.nexsen.bio

Name Title Year Born
Mr. Reece O'Connell Executive Chairman NA
Mr. Mark Anthony Muzzin B.A. Founder, MD, Advisory Board Member & Director 1963
Mr. Richard Mark Jarvis Chief Financial Officer 1974
Dr. Sanje Mahasivam Research Team Leader & CTO NA
Prof. Vipul Bansal Chief Innovation Officer & Advisory Board Chair NA
Mr. Sonny Didugu Company Secretary NA
Mr. Mark Anthony Muzzin B.A. Founder, MD, Advisory Board Member & Executive Director 1963
Prof. Shekhar Kumta Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…